Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin
關(guān)愛(ài)生命與健康 為人類(lèi)健康做出貢獻(xiàn)
Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin
Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression
The Human Epidermal Growth Factor Receptor family is composed of 4 structurally related receptor tyrosine kinases that are involved in many human cancers The efficacy and safety of HER inhibitors have been compared in a wide range of clinical trials, suggesting the superior inhibitory ability of multiple- HER-targeting blockade compared with single receptor antagonists However, many patients are currently resistant to current therapeutic treatment and novel strategies are warranted to
Honokiol (3 ,5-di-(2-propenyl)-1,1 -biphenyl-2,4 -diol) is a bioactive natural product derived from Magnolia spp Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB)
Background: Overexpression of survivin is associated with resistance to radiotherapy and poor survival in many cancer types However, in squamous cells carcinoma of head and neck (SCCHN), previous studies have revealed diverging results regarding survivin s role in clinical outcome In this study, we aim to 1) evaluate the clinical significance of survivin expression in SCCHN; 2)